Drug Trial Radar · NCT07588568
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Feb 2030
Study completion Jun 2030
Sponsor
- Lead sponsor
- University of North Carolina, Chapel HillAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); AbbVie; University of California, San Diego; La Jolla Institute for Immunology; Duke University
- First posted
- May 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE). The main question it aims to answer are: \- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity? Participants will: * Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib * Fill out surveys and answer health questions * Visit the clinic every 4 weeks for checkups and tests
Conditions
- EoE
- Eosinophilic Esophagitis
- Eosinophilic Esophagitis (EoE)
Interventions
Upadacitinib 30mg DoseDrug
Upadacitinib 30mg oral tablet. Participants randomly assigned to receive upadacitinib will take upadacitinib 30mg daily throughout the study. Participants randomly assigned to receive placebo will receive upadacitinib for 12 weeks after completing the 12 week blinded treatment period.
Upadacitinib Matching PlaceboOther
Oral tablet matching in size, shape, color, and taste to the study intervention (upadacitinib). Participants randomly assigned to receive placebo will receive upadacitinib matching placebo for 12 weeks, followed by a 12 week open label treatment period where all participants will receive upadacitinib 30mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak eosinophil count (measured in eos/hpf) after 12-weeks of treatmentTime frame: At 12-weeks post-treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Duke University
Durham, North Carolina · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.